EMH
0.38
58.3%
BP8
0.001
-50%
RDS
0.003
50%
C7A
0.002
-33.3%
PIL
0.004
33.3%
VEE
0.86
-25.5%
CRI
0.029
31.8%
PGY
0.003
-25%
GCM
0.017
30.8%
BLU
0.004
-20%
EPM
0.023
27.8%
BYH
0.004
-20%
CQT
0.049
25.6%
MAUCA
0.905
-17.4%
DTM
0.055
25%
CAV
0.005
-16.7%
H2G
0.01
25%
MAY
0.012
-14.3%
RLG
0.005
25%
G88
0.007
-12.5%
SIS
0.005
25%
GRL
0.014
-12.5%
LKE
0.072
22%
PER
0.007
-12.5%
GT1
0.045
21.6%
M3M
0.029
-12.1%
GW1
0.045
21.6%
PHX
0.145
-12.1%
ICL
0.064
20.8%
LML
0.008
-11.1%
CZN
0.18
20%
PL9
0.008
-11.1%
EGY
0.024
20%
RCR
0.016
-11.1%
PLC
0.006
20%
G11DA
0.29
-10.8%
VAR
0.006
20%
KPO
0.017
-10.5%
STG
0.34
19.3%
PEB
0.13
-10.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT U.S. FDA accepted new drug application

Botanix Pharmaceuticals’ (ASX:BOT) resubmission of its New Drug Application for Sofdra has been accepted by the U.S. FDA. As a result, approval of the gel is targeted for June 2024 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20240122/pdf/05zm3xd62ktg15.pdf #FDA #DrugApproval #ASX